Novartis to Buy Breast Cancer Drug for as Much as $3 Billion

Chronological Source Flow
Back

AI Fusion Summary

Novartis acquires experimental breast cancer drug SNV4818 from Synnovation for $2B upfront, with potential $1B milestone payments. Oral therapy targets mutant PI3K in HR‑positive, HER2‑negative breast cancer, currently in Phase 1/2 trials.
#Novartis #breast cancer #PI3K inhibitor #Synnovation Therapeutics #drug acquisition #Phase 1/2 trial #milestone payments #oral therapy
20/03 08:54 bloomberg.com
3 Πηγές

Novartis to Buy Breast Cancer Drug for as Much as $3 Billion

VTX:NOVN
20/03 10:22 statnews.com

STAT+: Novartis picks up experimental breast cancer drug for $2B

Novartisbreast cancerPI3K inhibitorSynnovation Therapeuticsdrug acquisitionPhase 1/2 trial
20/03 10:42 investing.com

Novartis to buy experimental breast cancer drug in up to $3 billion deal

Comments
Loading...
0